Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALV - KalVista Pharmaceuticals Inc

IEX Last Trade
13.39
0.390   2.913%

Share volume: 725,197
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$13.00
0.39
3.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 4%
Liquidity 75%
Performance 18%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
6.02%
1 Month
-6.17%
3 Months
19.02%
6 Months
0   0%
1 Year
17.97%
2 Year
-17.90%
Key data
Stock price
$13.39
P/E Ratio 
-15.23
DAY RANGE
$12.67 - N/A
EPS 
-$2.12
52 WEEK RANGE
$7.21 - $16.88
52 WEEK CHANGE
$0.26
MARKET CAP 
576.867 M
YIELD 
N/A
SHARES OUTSTANDING 
43.082 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/05/2024
BETA 
1.08
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$279,300
AVERAGE 30 VOLUME 
$234,188
Company detail
CEO: Thomas Crockett
Region: US
Website: http://www.kalvista.com/
Employees: 95
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Recent news